Category Archives: Genetic Engineering

By James Chesters 16 July 2024 4 min read

Senior scientist Thomas Vanhercke didnt plan his career as much as he could have. When he was growing up, he followed his passion instead.

"In science you must be driven by passion, an insatiable thirst for knowledge, and lots of patience, Thomas says.

People always say to follow your heart. It might seem trivial, but its very important.

Following his passion has made Thomas who he is today. His passion for genetics started in high school. Then, he pursued a MSc and PhD in Bioengineering at Ghent University the birthplace of plant genetic engineering.Thomas was intrigued by how genetic research can be applied in agriculture.

Today, Thomas passion and skills make him an expert in metabolic engineering and synthetic biology. This involves genetically engineering microbes and plants to produce specific ingredients and molecules.Thomas leads teams tackling some of the biggest hurdles in food and agriculture.

Thomas Vanhercke currently leads our Synthetic Traits group, overseeing novel protein production research for our Future Protein mission.

Our agricultural and food systems face some serious challenges. From adapting to a changing climate to shifting towards more sustainable practices, Thomas says.

By 2050, the global population will reach 9.7 billion . This will cause the worlds annual demand for protein to almost double. With no more land available for grazing cattle, our current ways of producing protein cant meet future demand.

Malnutrition also remains one of the worlds greatest challenges. Even if food is readily available, people are often undernourished. This is from diets lacking in micronutrients like iron and zinc.

But Thomas is fascinated with how genetic engineering can unlock solutions to agricultural challenges. He sees opportunities where others see problems.

Our Future Protein research brings together expertise from many scientific disciplines and sectors. Were here to tackle the challenges ahead through a coordinated and sustained effort.

Thomas oversees novel protein production research for our Future Protein purpose-led innovation initiative. This means harnessing the potential in existing food streams to produce high-value ingredients.

Technologies like precision fermentation and molecular farming sound futuristic. But they help complement traditional food systems, such as livestock and broadacre crops.

Our scientists use precision fermentation and molecular farming to engineer microbes and plants. Theyre cooking up specific, customised molecules to serve as new ingredients. These will enhance the taste, texture, colour or mouthfeel of our foods.

This process has a long and safe history in supplementing and diversifying our foods. Technological advances have brought down the cost of precision fermentation. So now were using it to create new, high-value food products.

Were not just improving the consumer experience. Precision fermentation can create ingredients that address other concerns such as sustainability, nutrition, or animal welfare, Thomas says.

Red meat, dairy, and seafood are here to stay. These animal-based proteins will continue playing a vital role in human diets globally.

Proteins made through precision fermentation using ingredients like yeast complement animal-based sources. Theyll help us meet growing demand, without sacrificing on quality. This holistic approach offers more protein choices to suit individual dietary, nutritional and taste preferences.

Were not just improving the consumer experience. Precision fermentation can create ingredients that address other concerns such as sustainability, nutrition, or animal welfare, Thomas says.

Thomas says were starting to see lot of activity and investment in this space. This includes developing hybrid food products that combine animal-, plant- and fermentation-derived ingredients.

I think the next exciting frontier will be the boundaries between different food production systems. For example, making sure that no food byproducts go to waste, he says.

Thomas also heads up our Synthetic Traits research, applying engineering principles to plants. Their successes include developing the science for canola crops with high levels of healthy omega-3 oils.

Synthetic biology applies engineering principles to biology. In other words, creating solutions from natures building blocks.

For example, Thomas and his team are working on new crops that can convert their own nitrogen for growth. This will help farmers to use less nitrogen fertiliser which impacts the environment while still growing enough food.

Thomas is clear that great science needs diversity. He believes that innovation relies on people with different knowledge and skills coming together. This diversity could range from technical expertise to research infrastructure. It incorporates business development and intellectual property knowledge, as well as delving into market trends.

No one can do everything by themselves, we each stand on the shoulders of many others, Thomas says.

Diversity of knowledge, experience, and thought are critical, he says.

Thomas has big ideas about how to inspire the next generation of scientists. He believes role models, mentoring, and a strong science curriculum are all important.

I encountered several inspiring people along the way who have gently helped me in stepping outside my comfort zones and have pushed me in the right direction, Thomas says.

Hopefully I am continuing their example by inspiring others around me.

Since taking on more responsibilities as a leader, Thomas doesnt get to spend as much time in the lab. Sometimes wearing a white coat can feel odd. But he takes satisfaction in mentoring others and seeing the excitement when a great result comes in.

Thomas doesnt hesitate when asked what he enjoys most about his work.

I love collaborating with colleagues from diverse science backgrounds when developing new ideas. And thinking about the next frontier in research innovation and impact. That is really the coolest part of my job, he says.

Continue reading here:
Meet Thomas Vanhercke: innovating with passion - CSIRO

Chinese scientists have reportedly engineered a way to use gene-editing technology to bypass natural plant behavior and force crops to inherit genes that will make them more resilient and easier to grow, according to Interesting Engineering.

"The genetic manipulation of wild plant populations has emerged as a potentially powerful and transformative strategy," the researchers said.

The technique involves using CRISPR gene-editing technology to bypass traditional Mendelian inheritance the process by which genes are passed down through generations to breed plants with "ideal" genes. The system is known as CRISPR-Assisted Inheritance, or CAIN.

"This gene drive-based approach thus seeks to balance crop protection and environmental considerations to minimise the loss of biodiversity while optimising productivity," the researchers wrote. "As we venture into this new frontier in genetic engineering, [CAIN] and other gene drive systems could reshape ecological management and agricultural practices."

All around the world, food supplies are being threatened by the consequences of human activities mainly, the usage of dirty energy sources like gas and oil that have caused our planet to overheat and weather patterns to become extreme and unpredictable. Rising global temperatures and increasingly widespread droughts have made many crops nonviable in areas where they have traditionally been grown.

It is vital that we stop this trend in its tracks by turning away from dirty energy and relying instead on clean, renewable sources of energy such as wind and solar.

Join our newsletter Good news, green hacks, and the latest cool clean tech straight to your inbox every week!

However, in the meantime, we must use technology to create more sustainable agricultural practices and food sources that can withstand more extreme weather conditions.

Some recent innovations in that field include the discovery of a genetic mechanism in pear trees that allows them to tolerate drought conditions, the discovery of a gene mutation in peach trees that lets them escape the effects of spring frost, and a genome-edited type of rice that is resistant to a devastating virus.

Any of these discoveries and breakthroughs could be applied to other crops, using CRISPR technology, to make them more resilient as well.

Join our free newsletter for weekly updates on the coolest innovations improving our lives and saving our planet.

Visit link:
Chinese researchers make genetic breakthrough that could change the future of agriculture: 'Powerful and transformative strategy' - The Cool Down

NEW YORK, July 17, 2024 /PRNewswire/ -- The globalgenetically modified (GMO) food marketsize is estimated to grow by USD 46.8 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 7.07% during the forecast period. High demand for crop productionis driving market growth,with a trend towardsinnovations in gene-editing technologies. However,increase in demand for organic food products poses a challenge. Key market players include BASF SE, Bayer AG, Cibus, Corteva Inc., FMC Corp., Groupe Limagrain, JK Agri Genetics Ltd., KWS SAAT SE and Co. KGaA, Rasi Seeds P Ltd., Sakata Seed Corp., Stine Seed Co., Syngenta Crop Protection AG, Tata Sons Pvt. Ltd., Terranova Seeds Australia, and UPL Ltd..

Get a detailed analysis on regions, market segments, customer landscape, and companies-View the snapshot of this report

Genetically Modified (GMO) Food Market Scope

Report Coverage

Details

Base year

2023

Historic period

2017 - 2021

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 7.07%

Market growth 2024-2028

USD 46.8 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

6.43

Regional analysis

North America, APAC, Europe, South America, and Middle East and Africa

Performing market contribution

APAC at 35%

Key countries

US, China, Japan, Canada, and France

Key companies profiled

BASF SE, Bayer AG, Cibus, Corteva Inc., FMC Corp., Groupe Limagrain, JK Agri Genetics Ltd., KWS SAAT SE and Co. KGaA, Rasi Seeds P Ltd., Sakata Seed Corp., Stine Seed Co., Syngenta Crop Protection AG, Tata Sons Pvt. Ltd., Terranova Seeds Australia, and UPL Ltd.

Market Driver

The global genetically modified food market is experiencing significant growth due to the premium pricing of non-genetically modified food products. Consumers, while health-conscious, often base their purchasing decisions on affordability. In the US, over half of the population expresses concerns about genetically modified food, but the health effects remain unclear. As non-genetically modified food prices continue to rise, consumers may switch to genetically modified alternatives during the forecast period. Reasonable pricing and uncertainty surrounding the health effects of genetically modified food are key factors driving market growth.

Genetically Modified (GMO) food market is witnessing significant trends in food security through the use of gene technology and genome editing. Key crops like herbicide resistant soybeans, insecticide resistant soybeans, corn, canola, sweet potato, rice, and others are being modified to increase yield and reduce reliance on harmful pesticides. New innovations include the addition of essential nutrients like iron and vitamins in foods, such as bananas and rice. Recombinant DNA technology and transgenic crops are revolutionizing the industry, leading to the production of vaccines for infectious diseases like Hepatitis B, and even new plastics. However, there are risks and controversies surrounding GMOs, including health concerns, consumer choice, ethics, and environmental impact. Mechanisms for labeling and public education are crucial to address these issues and ensure food safety. New technologies, such as gene manipulation, continue to emerge, raising questions about potential allergens and antibiotic resistance. The market for genetically modified foods, also known as transgenic and genetically engineered foods, is expected to grow, but addressing public concerns and ensuring safety remains a top priority. The potential for poverty reduction and advancements in fish farming and human health are also significant opportunities for the industry.

Discover 360 analysis of this market. For complete information, schedule your consultation -Book Here!

MarketChallenges

For more insights on driver and challenges-Request asample report!

Segment Overview

This genetically modified (gmo) food market report extensively covers market segmentation by

1.1 Vegetables- Genetically modified vegetables offer advantages such as faster growth and higher yields, making them valuable in meeting the increasing food demand. These modifications also provide resistance to pests and diseases, reducing the need for chemical pesticides and minimizing crop losses. Additionally, genetically modified vegetables can withstand extreme weather conditions, enhancing their resilience to climate change. The global vegetable market is expected to grow due to factors like the expanding food industry, rising consumer expenditure, and increasing health consciousness. The vegetable segment is particularly driven by the growing vegan population and the demand for exotic vegetables. Consumers in both developed and developing nations have higher disposable incomes, leading to increased demand. Genetically modified vegetables are accessible through offline and online retail channels, with the latter gaining popularity due to the convenience and wide variety of offerings, including exotic vegetables. The growing disposable income, especially in emerging economies, and the demand for exotic vegetables will fuel the growth of the vegetable segment in the global genetically modified food market.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) - Download a Sample Report

Learn and explore more about Technavio's in-depth research reports

The global plant-based protein products market is witnessing robust growth due to rising health consciousness and increasing veganism trends. Key players are innovating to meet the demand for sustainable and nutritious alternatives. Similarly, the global non-GMO food market is expanding as consumers seek healthier and more natural food options. The demand for transparency and food safety is driving this market, with significant contributions from major food brands and organic producers. Both markets are poised for substantial growth, driven by consumer preferences and evolving dietary trends.

Research Analysis

The genetically modified (GMO) food market refers to the production and consumption of nutrition-rich foods derived from organisms with altered genetic structures. This involves the use of genetic modification techniques, such as gene technology and recombinant DNA technology, to introduce better characteristics into plants and animals. Edible organisms, including soybeans, cotton, corn, canola, and sweet potato, are commonly modified to enhance traits like herbicide tolerance, insect resistance, and stacked traits. These modifications aim to improve conditions for farmers, such as increased shelf life and resistance to pests, while maintaining or enhancing the nutritional value of the food. Microorganisms are also used in the production of GMO foods through various genetic engineering techniques. The result is a diverse range of transgenic crops and herbicide resistant soybeans, insecticide resistant soybeans, and other GMO foods that offer improved characteristics for farmers and consumers alike.

Market Research Overview

The Genetically Modified (GM) food market encompasses a wide range of nutrition-rich foods derived from genetically modified organisms (GMOs), including plants and animals. These edible organisms exhibit better characteristics under specific conditions, such as longer shelf life, sweet flavor, and better texture, making them highly sought-after in today's global market. The demand for GM foods continues to grow due to their health benefits, which include combating diseases like cancer and gastrointestinal discomfort, as well as addressing allergies caused by pesticides and toxic substances. Innovative products in the GM food market include beverages, food processing techniques, and taste preferences. Genetic engineering techniques, such as gene guns, electroporation, microinjection, Agrobacterium, transgenic, cis-genic, and sub-genic methods, are used to introduce desirable traits like herbicide tolerance, insect resistance, and stacked traits into agricultural crops, animal feed, and even food waste reduction. Trait types include nitrogen fixing crops, haploid induction techniques, and gene stacking, among others. Companies like Origin Agritech, Monsanto, COODETEC, Nidera, Sensako, and others are at the forefront of this industry, driving food security through genome editing, gene technology, and the development of living organisms and microorganisms using recombinant DNA technology. GM foods extend beyond crops to include transgenic soybeans, corn, canola, sweet potato, rice, and even human vaccines for infectious diseases like hepatitis B. The future of the GM food market holds exciting possibilities, with the advent of CRISPR technologies and the development of iron-fortified bananas and vitamin-enriched rice.

Table of Contents:

1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation

7Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email:[emailprotected] Website:www.technavio.com/

SOURCE Technavio

View post:
Genetically Modified (GMO) Food Market size is set to grow by USD 46.8 billion from 2024-2028, High demand for crop production boost the market,...

Over the past few years more and more companies have been hitting the food market with enticing offers of plant-based protein.

While this may be great news for vegans, plant-based proteins are incomplete because they are low in at least one essential amino acid. Animal-based proteins, meanwhile, contain all nine essential amino acids.

But what if we were to find a way to produce animal protein from plants?

Israel-based startup PoLoPo says it can produce protein from potatoes that is identical to protein derived from chicken eggs.

We use the plant molecular farming method, which is production of valuable metabolites and proteins [through the manipulation of the cell factory] in the plant, PoLoPo CEO and cofounder Maya Sapir-Mir tells ISRAEL21c.

We teach the plant to generate properties that originate in a completely different biological source, she adds.

Essentially, molecular farming entails insertion of genes useful for food production, through genetic engineering, into host plants that would otherwise not express those genes.

Regular potatoes already contain protein, but in very small quantities. Through molecular farming, PoLoPo specialists have created a new strain of potatoes.

The company claims this one-of-a-kind strain produces a lot more protein, and its molecular consistency is indistinguishable from egg protein, which is rich in ovalbumin a major protein component of egg white.

Our market product will be functional protein powder generated from our potato strain, explains Sapir-Mir.

PoLoPo was officially founded in 2022 by Sapir-Mir and her longtime research partner, Raya Liberman-Aloni.

The two plant scientists met 17 years ago during their doctoral studies at the Hebrew University of Jerusalem, specializing in metabolic engineering of plants.

We were researching the behavior of proteins in plants from citrus fruits to tomatoes, and even tobacco, explains Sapir-Mir.

We were always the odd ones out in academia, she laughs.

In 2017, the two women came up with a business idea to create a plant that produces animal protein for the food industry.

It took us some time to settle on potatoes, but once we got there, all the other pieces started falling into place.

PoLoPo is still in the research and development (R&D) phase. It has raised over $2 million so far in its first and only funding round, which allowed the company to weather the storm of October 7 relatively unscathed.

We have just opened our second funding round that hopefully will jumpstart us from the R&D phase to commercial phase, says Sapir-Mir.

The company, which has six full-time employees and three part-time workers, hopes its product will hit the market by 2027.

Sapir-Mir admits, however, the company will not be able to operate commercially in Israel or Europe due to strict regulations applied on GMO (genetically modified organisms) products.

The plan is to first enter the market in the United States. Weve already applied for a USDA permit to grow our plants in the US, she explains.

She adds that in the future the restrictions on genetically modified food products in Israel and Europe will likely be eased because theres no food security without GMO.

The food industry utilizes egg protein, normally generated from egg whites, in very, very large quantities, explains Sapir-Mir.

Ovalbumin has a host of valuable and functional properties revered by the food industry.

If you were to take a random product off a supermarket shelf and look at the label, theres a good chance youd see egg protein among the ingredients, she says.

Sapir-Mir adds that egg protein is used commercially in sweets, meat products, baked goods and even plant-based milk.

Once our product becomes fully commercialized, scaleup will be very easy. And at full scale, we will have competitive pricing compared to other commercial egg proteins on the market, notes Sapir-Mir.

Our hope is that one day our product replaces egg protein entirely.

YOU CAN GET ISRAEL21c NEWS DELIVERED STRAIGHT TO YOUR INBOX.

Read more:
PoLoPo: The startup making egg protein from potatoes - ISRAEL21c

WASHINGTON D.C. --Chairman John Moolenaar (R-MI) of the House Select Committee on the Chinese Communist Party wrote to Secretary of Agriculture Tom Vilsack, inquiring why the U.S. Department of Agriculture greenlit a Chinese agricultural biotech company with close links to the Chinese government operating in the United States. The firm, Qi Biodesign, is a company that makes genetically engineered soybean seeds and was prioritized for USDA regulatory approval ahead of many American agricultural companies that currently face extensive delays.

Select Committee Members Neal Dunn (R-FL), Dusty Johnson (SD), Ashley Hinson (R-IA), Carlos Gimenez (R-FL), and Ben Cline (R-VA) joined the letter.

The lawmakers outline a host of concerns writing,Qi Biodesign and other PRC firms like it are directly supported by the PRC government with the explicit purpose to replicate and replace U.S. agriculture biotechnology. While the PRC is clear-eyed about its desire to never allow its agriculture industry to be reliant on foreign technology, it appears the USDA is approving PRC agriculture biotechnology without concern for U.S. supply chains or trade negotiations. USDAs clearance of Qi Biodesigns products undermines years of hard-nosed U.S. trade demands and could make U.S. farmers complicit in the PRCs desire to replace them.

In an era when the Chinese government forbids U.S. agricultural companies from operating in China, Chairman Moolenaar underscores how perplexing it is for USDA to extend these benefits to companies beholden to our chief adversary. Moreover, the decision to welcome a Chinese government-backed company that sells genetically engineered soybeans into the U.S. raises serious questions for American consumers that mistrust genetic engineering in China.

Government-backed actors from China also have a long history of stealing U.S. agricultural intellectual property, with some going as far as digging up seeds in U.S. farm fields to smuggle back to China. In light of the growing threat, Chairman Moolenaar requests the Secretary of Agriculture that immediately revisit the regulatory status review for Qi Biodesign and asks for a briefing to address the following questions:

Read the lawmakers' letter to the FDAHERE.

Read the original post:
Moolenaar, Lawmakers Seek Answers After USDA Approves Chinese Genetically Engineered Soybeans - Select Committee on the CCP |

Reading Time: 3 minutes

Cloned food is entering Canadian markets without mandatory labelling

Health Canadas recent round of consultations, conducted with minimal public awareness, suggests that these products may soon be available without consumers knowledge, as there will be no mandatory labelling. The absence of such information on Health Canadas website only adds to the opacity surrounding cloned products.

The consultation, which concluded on May 25th, focused on updating the Policy on Foods Derived from Cloned Animals by Somatic Cell Nuclear Transfer and Their Progeny. This update proposes that cloned products be exempt from pre-market evaluation under Part B, Title 28 of the Food and Drug Regulations. This approach differs from other nations like the United States, Japan, and New Zealand.

But what precisely is animal cloning? The process aims to create a genetic replica of an animal by replacing the nucleus of an unfertilized egg with that of a somatic cell from the donor animal, forming an embryo. This embryo is then implanted into a surrogate mothers uterus, where it develops to term.

Artificial insemination, a well-established industry practice, involves collecting sperm from a male and artificially introducing it into a females reproductive system to facilitate fertilization, preserving genetic variability. Cloning, however, produces genetically identical animals, eliminating this variability.

From a food safety perspective, cloned products do not pose a threat to human health. However, the social and moral acceptability of cloning remains in question. It is doubtful that consumers will unconditionally accept this technology, especially in the absence of labelling. For traditional producers, integrating cloned products into the market could also taint consumer perceptions across entire categories, particularly meat and dairy.

This situation mirrors the backlash against genetically modified salmon, which faced immediate retail rejection despite being deemed safe. Irrespective of the safety profile, it is crucial to explain the technology and ensure consumers comprehend the rationale and necessity for such practices, both for their benefit and that of the industry.

For the industry, the imperative to amend regulations is less evident. Cloning is an expensive process, and the argument that reduced production costs will translate into lower retail prices for consumers is tenuous at best.

Without mandatory labelling, offering consumers a truly informed choice becomes problematic. We have witnessed similar issues with genetic engineering and GMOs. Health Canada appears poised to embrace technological advancements impacting our agri-food sector without adequately considering consumer rights and preferences.

Quite shameful.

Dr. Sylvain Charlebois is senior director of the agri-food analytics lab and a professor in food distribution and policy at Dalhousie University.

For interview requests, click here.

The opinions expressed by our columnists and contributors are theirs alone and do not inherently or expressly reflect the views of our publication.

Troy Media Troy Media is an editorial content provider to media outlets and its own hosted community news outlets across Canada.

Read this article:
Cloned meat on the menu? - Troy Media

Cloned food is entering Canadian markets without mandatory labelling.

Imagine savouring a steak from a cloned animal or sipping milk from a cloned cow. Investigative journalism by Thomas Gerbet of the CBC has revealed that this could soon be a reality. However, many agricultural producer groups have not been directly consulted about this development.

Health Canadas recent round of consultations, conducted with minimal public awareness, suggests that these products may soon be available without consumers knowledge, as there will be no mandatory labelling. The absence of such information on Health Canadas website only adds to the opacity surrounding cloned products.

The consultation, which concluded on May 25th, focused on updating the Policy on Foods Derived from Cloned Animals by Somatic Cell Nuclear Transfer and Their Progeny. This update proposes that cloned products be exempt from pre-market evaluation under Part B, Title 28 of the Food and Drug Regulations. This approach differs from other nations like the United States, Japan, and New Zealand.

But what precisely is animal cloning? The process aims to create a genetic replica of an animal by replacing the nucleus of an unfertilized egg with that of a somatic cell from the donor animal, forming an embryo. This embryo is then implanted into a surrogate mothers uterus, where it develops to term.

Artificial insemination, a well-established industry practice, involves collecting sperm from a male and artificially introducing it into a females reproductive system to facilitate fertilization, preserving genetic variability. Cloning, however, produces genetically identical animals, eliminating this variability.

From a food safety perspective, cloned products do not pose a threat to human health. However, the social and moral acceptability of cloning remains in question. It is doubtful that consumers will unconditionally accept this technology, especially in the absence of labelling. For traditional producers, integrating cloned products into the market could also taint consumer perceptions across entire categories, particularly meat and dairy.

This situation mirrors the backlash against genetically modified salmon, which faced immediate retail rejection despite being deemed safe. Irrespective of the safety profile, it is crucial to explain the technology and ensure consumers comprehend the rationale and necessity for such practices, both for their benefit and that of the industry.

For the industry, the imperative to amend regulations is less evident. Cloning is an expensive process, and the argument that reduced production costs will translate into lower retail prices for consumers is tenuous at best.

Without mandatory labelling, offering consumers a truly informed choice becomes problematic. We have witnessed similar issues with genetic engineering and GMOs. Health Canada appears poised to embrace technological advancements impacting our agri-food sector without adequately considering consumer rights and preferences.

Quite shameful.

Dr. Sylvain Charlebois is senior director of the agri-food analytics lab and a professor in food distribution and policy at Dalhousie University.

Troy Media

Originally posted here:
Opinion: You'll soon be eating cloned meat without knowing it - SaskToday.ca

The global gene synthesis market size surpassed USD 2.10 billion in 2023 and is projected to reach approximately USD 9.38 billion by 2033, expanding at a CAGR of 16.14% from 2024 to 2033. The gene synthesis market is experiencing significant growth due to advancements is synthetic biology, increased demand for personalized medicine and growing applications in drug development and research.

Download a sample version of gene synthesis market report @ https://www.towardshealthcare.com/personalized-scope/5170

Key takeaways

Gene synthesis is a laboratory method for creating artificial genes. Instead of extracting DNA from a living organism, scientists use chemical processes to build DNA sequences from scratch. This allows for the creation of custom DNA sequences that can be used in research, medicine and biotechnology. The ability to design and produce specific genes opens up a wide range of possibilities, from studying genetic functions to developing new treatments for diseases.

The gene synthesis market refers to the industry involved in producing and selling synthetic genes and related services. This market includes companies that offer custom DNA synthesis, where researchers can order specific DNA sequences tailored to their needs. The market has been growing rapidly due to advancements in technology, which have made gene synthesis more efficient and affordable.

Gene synthesis market at a glance

The gene synthesis market has seen remarkable growth and is poised for significant expansion over the next decade. This impressive growth can be attributed to the increasing demand for gene therapy and personalized treatments, which are becoming pivotal in modern healthcare and research.

The gene synthesis market encompasses various segments based on methods, services, and applications. Among the methods, solid-phase synthesis held the largest market share in 2023. This technique is widely used due to its efficiency and reliability in creating complex DNA sequences. In terms of services, antibody DNA synthesis dominated the market in 2023, reflecting the growing need for recombinant antibodies in research, diagnostics, and therapeutic applications. Meanwhile, viral DNA synthesis is expected to grow at the fastest rate during the forecast period, highlighting its importance in studying viral genetics and developing related therapies.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Advancements in Genomics and next-generation Sequencing (NGS) to act as a Driver

Advancements in genomics and next-generation sequencing (NGS) are major drivers for the gene synthesis market. These cutting-edge technologies enable scientists to quickly and accurately identify genes associated with various diseases, paving the way for the development of targeted therapies. Gene synthesis is crucial in this process as it provides the DNA constructs necessary for these applications.

Next-generation sequencing has revolutionized the field of genomics by allowing the sequencing of entire genomes at an unprecedented speed and accuracy. This capability has led to significant breakthroughs in understanding genetic disorders, cancers, and other complex diseases. For instance, by identifying specific genetic mutations responsible for certain types of cancer, researchers can develop targeted therapies that specifically attack cancer cells without harming healthy ones.

A recent example of advancements in this area is the development of CRISPR-based therapies. CRISPR, a gene-editing technology, relies heavily on synthetic DNA sequences to guide the editing process. Companies like CRISPR Therapeutics and Editas Medicine are using gene synthesis to create precise DNA sequences that can edit genes associated with diseases such as sickle cell anemia and beta-thalassemia.

Rise of Gene Editing Technologies Like CRISPR to Promote the Markets Growth

The rise of gene editing technologies, particularly CRISPR, is a significant driver of the gene synthesis market. CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, allows scientists to make precise and efficient changes to the DNA of living organisms. This technology has opened new avenues for gene therapy, creating a surge in demand for synthetic DNA fragments used in these therapies.

CRISPR's ability to target specific genes with unprecedented accuracy makes it a powerful tool in medical research and treatment. For example, researchers can use CRISPR to correct genetic mutations that cause diseases such as cystic fibrosis or muscular dystrophy. By inserting, deleting, or altering segments of DNA, CRISPR can potentially cure genetic disorders at their source.

Customize this study as per your requirement @ https://www.towardshealthcare.com/customization/5170

Skilled Workforce Shortage to Hamper the Markets Growth

One significant restraint on the gene synthesis market is the shortage of a skilled workforce. Gene synthesis is a complex process that requires specialized knowledge and expertise to operate and maintain advanced equipment. This lack of skilled professionals can hinder the market's growth, particularly in emerging regions where educational and training facilities may be less developed.

Gene synthesis involves several sophisticated techniques, including DNA sequencing, oligonucleotide synthesis, and the use of bioinformatics tools. These processes require a deep understanding of molecular biology, genetics, and biochemistry.

For example, many emerging markets in Asia, Africa and Latin America are experiencing rapid growth in biotechnology and life sciences. However, these regions often face challenges in attracting and retaining skilled professionals.

A recent development highlighting this issue is the global push for educational programs focused on biotechnology and gene synthesis. In 2023, several universities in India and China launched specialized courses aimed at training students in advanced genetic engineering and synthetic biology. These programs are designed to bridge the skill gap and produce a new generation of scientists proficient in gene synthesis technologies.

Xenotransplantation, An Emerging Opportunity for the Gene Synthesis Market

Xenotransplantation, the process of transplanting organs from animals to humans, represents a groundbreaking opportunity for the gene synthesis market. This field aims to address the chronic shortage of human organs available for transplantation by using genetically engineered animal organs. Gene synthesis plays a crucial role in this endeavor by enabling the precise genetic modifications needed to reduce organ rejection and improve compatibility with human recipients.

One of the major challenges in xenotransplantation is the human immune system's tendency to reject animal organs. To overcome this, scientists are using gene synthesis to modify the donor animal's genetic makeup, making the organs more acceptable to the human immune system. This involves inserting specific genes into the animal's DNA to produce proteins that can suppress immune responses, thus reducing the likelihood of rejection.

For example, recent advancements have been made in genetically modifying pigs, which are considered the most suitable donor animals due to their organ size and physiological similarities to humans. In 2022, a significant breakthrough was achieved when a team of researchers at the University of Maryland successfully transplanted a genetically modified pig heart into a human patient.

North America to Sustain as a Leader for the Market

North America has been a dominant force in the gene synthesis market, largely due to its strong focus on research and development. The United States leads the region with significant investments in biotechnology and synthetic biology. The presence of major biotech firms and well-established research institutions further bolsters market growth. The rising prevalence of genetic disorders and robust government support for scientific advancements contribute to the region's market leadership.

Europe is another significant player in the gene synthesis market, with countries like Germany, the United Kingdom, and France at the forefront. The region benefits from a strong academic and industrial research base, alongside substantial funding from both government and private sectors. The European Union's initiatives to support biotechnology and synthetic biology research have facilitated market growth.

Asia Pacific on to Grow at a Rapid Rate

Asia Pacific is expected to witness the fastest growth in the gene synthesis market during the forecast period. Countries like China, Japan, South Korea, and India are leading this growth. The region's expansion is fueled by increasing investments in biotechnology and genetic research, along with a growing number of biotech startups. Government initiatives to promote scientific research and healthcare advancements are also playing a crucial role.

India is emerging as a significant contributor to the gene synthesis market. The Indian government has launched several initiatives to support the biotechnology sector, recognizing its potential for economic growth and healthcare improvements. For instance, the Department of Biotechnology (DBT) has been funding numerous research projects and startups focused on gene synthesis and related technologies.

By Method, the Solid-phase Synthesis Segment Held the Largest Share in 2023

Solid-phase synthesis is the leading method in gene synthesis, favored for its efficiency and versatility in creating complex peptide-based molecules. It simplifies the purification process, accelerates the production of peptide intermediates, and ensures uniform particle sizes. This method's straightforward equipment and minimal environmental impact make it cost-effective, facilitating large-scale peptide synthesis used in various biotechnological applications.

By Services, the Antibody DNA Synthesis Segment Dominated the Market in 2023

Antibody DNA synthesis dominates the service segment of the gene synthesis market due to advancements in recombinant monoclonal antibody (rAb) technology. It plays a crucial role in developing modified antibody molecules used extensively in research, diagnostics, and therapeutic interventions. By automating the production of synthetic DNA products, this service supports the creation of recombinant antibodies (rAbs), vital for biological and toxicological research, as well as targeted therapies for conditions like autoimmune diseases and cancer.

By Application, the Gene & Cell Therapy Segment Dominated the Market

Among applications, gene & cell therapy development holds the largest share in the gene synthesis market. This segment leverages gene synthesis to engineers and insert artificial genes into cells, revolutionizing personalized medicine. It enables the creation of tailored treatments based on individual genetic profiles, known as pharmacogenetic and pharmacogenomic data. This approach aims to enhance patient care by providing precise and effective therapies that address specific genetic conditions and improve overall health outcomes.

Browse More Insights of Towards Healthcare:

Recent developments

Top Companies in the Gene Synthesis Market:

Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5170

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Browse our Brand-New Journals:

https://www.towardspackaging.com

https://www.towardsautomotive.com

https://www.precedenceresearch.com

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Get Our Freshly Printed Chronicle:https://www.healthcarewebwire.com

View original post here:
Gene Synthesis Market to Lead by 16.14% of CAGR to Hit USD 9.38 Billion by 2033 - BioSpace

Home Articles Reproductive Ethics, Genetic Engineering, and the Common Good

In November 2018, media outlets around the globe were abuzz with the news of the birth of twin girls with modified genes designed to make them immune to HIV. This groundbreaking and controversial experiment was conducted by He Jiankui, a Chinese biophysicist, who used CRISPR technology to disable the CCR5 gene, enabling HIV infection. However, He Jiankuis work, which aimed to immunize babies against HIV, was shrouded in controversy due to its ethical and legal implications. Chinese regulations prohibit research on human embryos beyond the fourteenth day of existence and their subsequent implantation into a uterus. Moreover, the scientific community was concerned about the potential unintended consequences, as the CCR5 gene is also associated with significant brain functions. This experiment might not only have prevented HIV but also inadvertently enhanced the intelligence and memory of the twin girls.

This event sparked intense debate over using CRISPR-Cas9, the latest gene-editing technology. Genetic engineering is not a new field; arguments for and against it have been made for years, and various regulations have attempted to provide legal and ethical frameworks, albeit incomplete and often controversial. However, CRISPR-Cas9 has revolutionized genetic engineering, potentially transforming public perception and ethical considerations surrounding gene editing.

The Canadian philosopher and Jesuit Bernard Lonergan offers a compelling interpretive framework for examining the epistemological and ethical dimensions of reproductive choices. His Critical Realism emphasizes the interplay between knowing and being, guiding us beyond individual interests toward a vision that values the collective welfare of humanity.

Lonergans seminal works, Insight and Method in Theology, provide a layered conception of goodfrom an elemental notion linked to desires objectives to the intrinsic Good of Value, fully comprehensible only within the context of moral conversion. This nuanced understanding is particularly relevant for todays debates on reproductive ethics, encouraging us to make decisions that harmonize technological potential with broader human well-being.

In Insight, Lonergan explores the nature of human understanding and how we come to know and discern truth. He introduces the idea of the good in a foundational sense, linked to the immediate objectives of our desires (i.e., particular goods). This basic level of good is what people seek instinctively, driven by their immediate needs and wants. However, Lonergan does not stop at this elemental notion.

In Method in Theology, he deepens this exploration by distinguishing between different levels of good:

1. Particular Goods (those of desire): This is the most basic level, where good is perceived as satisfying individual desires and needs. Its an immediate and often self-centered understanding of good.

2. The Good of Order: This level involves understanding good within the context of social structures and relationships. It recognizes that individual goods are interconnected and that a well-ordered society is necessary for individuals to flourish. Here, good transcends personal satisfaction and includes the well-being of the community.

3. The Good of Value: This is the highest level of good, which can only be fully comprehended through moral conversiona profound transformation of ones values and priorities. At this level, good is understood as that which genuinely enhances human dignity and promotes the common good. It involves a self-transcending love and commitment to what is genuinely worthwhile, beyond mere personal or immediate gain.

This more nuanced understanding of good is particularly relevant for todays debates on reproductive ethics. Modern technologies, such as CRISPR and other genetic modifications, offer unprecedented potential to alter human biology. However, decisions regarding their use should not be driven solely by the basic good of satisfying individual desires (such as selecting for desired traits) or even the societal good of preventing diseases. Instead, they should be guided by the higher good of value, which considers the broader implications for human dignity and the common good.

Notwithstanding, these advancements in reproductive technologies have, in some contexts, normalized the transition from a natural birth to a chosen birth. However, this heightened agency brings with it significant ethical considerations. The concept of the best baby, which includes not only rectifying genetic anomalies but also enhancing specific traits, raises fundamental questions about our understanding of human nature and the potential societal implications.

For instance, preferences for specific traits may vary widely across cultures, societies, and individuals, potentially leading to new forms of inequality and discrimination. Lonergans philosophy urges us to transcend individualistic aspirations and consider the collective impact of these choices on society.

Lonergans insights into the Common Good offer a comprehensive perspective that transcends individual welfare. He emphasizes a societal dimension where each individuals good contributes to and is enriched by the well-being of all. His philosophical constructs urge us to move beyond mere individualism and consider the collective welfare of humanity, particularly in the context of reproductive technologies.

This conception of the Good is multi-layered, encompassing different aspects of human desire and ethical reasoning. He differentiates between the Good of Order, which refers to the structured coordination of human actions toward common goals, and the Good of Value, understood within the context of moral conversion and deeper ethical commitment. This layered understanding is particularly relevant for todays debates on genetic modifications and reproductive choices.

Individual decisions regarding reproductive technologies have far-reaching implications. While promising to eliminate certain hereditary diseases or enhance specific traits, genetic modifications pose significant ethical challenges. How might these choices impact the human gene pool over generations? What are the potential ecological and biodiversity consequences of narrowing genetic variability?

Appropriating this framework helps us understand that modifying genes in human embryos can have long-term consequences on the human gene pool. By selectively enhancing or disabling certain traits, we risk creating new forms of inequality and potentially reducing genetic diversity, which is crucial for the resilience of our species. Decisions made today could set precedents that influence the genetic makeup of future generations, possibly leading to unintended health and societal issues.

The ecological implications of genetic modifications extend beyond humans. For instance, altering human genes might inadvertently affect our interaction with the environment and other species. Lonergans emphasis on the interconnectedness of all aspects of existence urges us to consider these broader ecological impacts. Narrowing genetic variability could reduce our ability to adapt to environmental changes, thereby impacting not just individual health but the sustainability of ecosystems.

If we adopt a critical realist approach, however, we can navigate these challenges with a focus on collective human flourishing. Lonergans philosophical approach advocates for informed and responsible decision-making processes that consider immediate benefits and long-term consequences. This perspective encourages us to look beyond individual desires and assess how our choices contribute to the Common Good, ultimately promoting a balanced approach that harmonizes technological potential with ethical integrity and communal well-being.

Fostering interdisciplinary dialogue and community engagement is essential to addressing these ethical considerations. Policymakers, medical professionals, and potential parents must collaborate to ensure that a commitment to the Common Good guides genetic interventions. This involves creating platforms for public discourse, ethical review boards, and comprehensive educational programs that integrate scientific knowledge with philosophical, theological, and ethical insights. By doing so, we can ensure that our advancements in reproductive technologies align with a vision of human flourishing that respects both individual rights and collective responsibilities.

Implementing policies and practices that reflect Lonergans ethical principles is essential to aligning reproductive technologies with the common good. This involves creating frameworks encouraging reflection, dialogue, and responsible decision-making across various sectors.

Policymakers play a crucial role in shaping the ethical landscape of reproductive technologies. To foster a community-centric approach, it is essential to establish policies that encourage dialogue and reflection on genetic choices. One effective measure could be the formation of Genetic Ethics Committees at both local and national levels. These committees would serve as forums for public discourse, bringing together diverse perspectives from ethicists, scientists, religious leaders, and laypersons. For example, town-hall-style meetings focused on emerging genetic technologies can provide a platform for citizens to voice concerns, hear expert opinions, and collaboratively shape policy directions.

Additionally, public funding should prioritize treatments that address life-threatening genetic disorders over aesthetic enhancements. Countries like Sweden have already taken steps in this direction, ensuring that public resources are channeled towards creating a healthier society rather than catering to superficial desires. Implementing policies that emphasize the Common Good can help prevent the commodification of human life and ensure that advancements in genetic technologies benefit society as a whole.

Within the context of Catholic doctrine, it is essential to emphasize the sanctity and dignity of human life from conception to natural death.

Concerning medical professionals, they are at the forefront of implementing and advising on reproductive technologies. To facilitate informed decision-making processes for potential parents, healthcare providers must ensure that individuals understand the broader implications of their choices. This can be achieved through in-depth, multi-session consultations beyond detailing medical procedures, including discussions on societal and ethical impacts. For instance, genetic counselors in Iceland have pioneered such comprehensive consultation models, enabling parents to make well-rounded decisions.

Introducing ethical case reviews in hospitals can also ensure that decisions are introspective and ethically sound. Regular interdisciplinary meetings involving sociologists, ethicists, and geneticists can help medical professionals stay informed about the societal impacts of genetic choices. These practices foster a holistic approach to patient care, ensuring that individual decisions align with the broader ethical framework that respects the Good of Order and the Good of Value.

Parents play a pivotal role in shaping the future through their reproductive choices. Within the context of Catholic doctrine, it is essential to emphasize the sanctity and dignity of human life from conception to natural death. Parents should be encouraged to reflect deeply on their motivations for considering any genetic interventions, ensuring that their decisions uphold the inherent worth of every human being as created in the image of God. Rather than focusing on selecting specific genetic traits, parents should consider the broader ethical implications and the potential societal impacts of their choices. Participation in church-led educational programs and ethical discussions can provide valuable guidance. These programs, facilitated by trained professionals and aligned with Church teachings, can help parents understand the moral dimensions of their decisions, encouraging them to act in ways that respect the sanctity of life and promote the Common Good.

Moreover, parents must recognize that every choice they make is part of a larger societal fabric. Understanding the long-term impacts on community values and human diversity can help ensure that their decisions contribute positively to the Common Good. Engaging in community dialogues within their parish or diocese can help parents consider how their choices might shape future generations and societal norms, always grounded in a respect for life and the teachings of the Church.

By grounding reproductive choices in Lonergans ethical framework and the Catholic tradition in which his approach was developed and emerged, we can navigate the complex landscape of genetic technologies, focusing on collective human flourishing without defaulting to reductionistic narratives and sterile utilitarian calculus. Policymakers, medical professionals, Church leaders, and parents all have roles to play in this endeavor. Encouraging policies that foster dialogue, provide comprehensive and ethical guidance, and promote introspective decision-making processes are essential steps in aligning reproductive technologies with the Common Good, something that sorely needs a recovery. This approach ensures that advancements in genetic engineering benefit individuals and contribute to societys holistic well-being, reflecting the multi-dimensional intricacies of human existence that Lonergan so profoundly emphasized.

See original here:
Reproductive Ethics, Genetic Engineering, and the Common Good - Word on Fire

Efforts to breed for ideal genes that can be detrimental to their plants have been limited by the classical principles of Mendelian inheritance and Darwinian natural selection, the team from the Chinese Academy of Sciences and Peking University said in their paper.

07:58

Why is the Chinese government so concerned about food security?

Why is the Chinese government so concerned about food security?

Mendelian inheritance is a principle that describes how genetic traits are passed from one generation to another, and states that the two alleles contained within a single gene each have a 50 per cent chance of passing on to offspring through reproduction.

Synthetic gene drives, inspired by natural selfish genetic elements and transmitted to progeny at super-Mendelian (greater than 50 per cent) frequencies, present transformative potential for disseminating traits that benefit humans throughout wild populations, even facing potential fitness costs, the team said.

A gene drive is a genetic engineering technique that allows genes to be modified in a way that discourages them from following the usual rules of heredity, thereby increasing the likelihood that a particular suite of genes will be passed onto the next generation and spread through a population.

The synthetic toxin in this case, a guide RNA Cas9 cassette was used to disrupt the No Pollen Germination 1 (NPG1) gene limiting pollen germination. A CRISPR-resistant antidote copy of NPG1 is then used to rescue pollen cells that carry the desired gene drive.

A red fluorescent seed marker was added to CAIN to track the progress of the gene drive.

CAIN transmission rates greatly exceeded the expected Mendelian inheritance of 50 per cent in heterozygous male parents, reaching 88 to 99 per cent within two successive generations, the team wrote.

We established CAIN as a state-of-the-art tool to efficiently modify entire plant populations.

01:54

CRISPR/Cas9: a gene-editing tool with promise and peril

CRISPR/Cas9: a gene-editing tool with promise and peril

CAIN has advantages over other gene drive systems, which can develop a higher amount of resistance alleles that limit their efficacy. Compared to other systems, the team said they also chose to target the male germline over the female germline, since toxin-antidote gene drives targeting the female germline can compromise fertility and limit efficiency.

CAIN could be used in a variety of plants, as NPG1 is conserved across many species. One potential use of the system would be to target herbicide resistant genes in weeds to help reduce the need for excessive herbicide spraying, according to the researchers.

This gene drive-based approach thus seeks to balance crop protection and environmental considerations to minimise the loss of biodiversity while optimising productivity, the researchers wrote.

The team acknowledged that even if gene drive technologies are biosafe and self-containment strategies are implemented, the strategies may not be feasible in cases of intentional misuse of gene drive technology, targeting domestic crops or wild plants.

One method to safeguard against misuse could be the intentional creation and if necessary, release of suppressor lines. Editing the native NPG1 allele to resist Cas9 cleavage is a particularly straightforward and efficient method, the team said.

As we venture into this new frontier in genetic engineering, [CAIN] and other gene drive systems could reshape ecological management and agricultural practices.

Read this article:
Chinese scientists find plant breeding loophole that could reshape food security - South China Morning Post